Population-based pan-Canadian EGFR-mutation testing program.

Tsao, Ming Sound; Ionescu, Diana N.; Chong, George; Magliocco, A. M.; Soulières, Denis; Hwang, Dong Soo; Young, Shin Soon; Cao, Wei; Bosdet, Ian; Karsan, Aly; Spatz, Alan; Kamel‐Reid, Suzanne

doi:10.1200/jco.2011.29.15_suppl.e18017

Cited by 2 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In fact, this scenario appeared when a pan-Canadian EGFR mutation-testing program was initially supported with funding from AstraZeneca Canada. There was rapid uptake of testing across the country, with approximately 250 tests per month performed [ 66 ]. When this program ended after 12 months, governmental funding was not yet in place and testing rates dropped to 50–100 tests per month.…”

Section: Challenges To Implementing Personalized Treatment Approacmentioning

confidence: 99%

Challenges in Implementing Personalized Medicine for Lung Cancer within a National Healthcare System

Dawe

Ellis

2012

JPM

View full text Add to dashboard Cite

The traditional approach to the treatment of advanced non-small cell lung cancer (NSCLC) relied on the uniform use of cytotoxic chemotherapy. Over the last eight years, this paradigm of care has been shifting towards the use of molecularly targeted agents. Epidermal growth factor receptor (EGFR) mutations have emerged as an important biomarker for these targeted agents and multiple studies have shown that tyrosine kinase inhibitors (TKI) that inhibit EGFR are superior to traditional chemotherapy in patients possessing an EGFR mutation. Nationally funded health care systems face a number of challenges in implementing these targeted therapies, most related to the need to test for biomarkers that predict likelihood of benefiting from the drug. These obstacles include the challenge of getting a large enough tissue sample, workload of involved specialists, reliability of subtyping in NSCLC, differences in biomarker tests, and the disconnect between the funding of drugs and the related biomarker test. In order to improve patient outcomes, in a national healthcare system, there is a need for governments to accept the changing paradigm, invest in technology and build capacity for molecular testing to facilitate the implementation of improved patient care.

show abstract

Section: Challenges To Implementing Personalized Treatment Approacmentioning

confidence: 99%

Challenges in Implementing Personalized Medicine for Lung Cancer within a National Healthcare System

Dawe

Ellis

2012

JPM

View full text Add to dashboard Cite

show abstract

“…In an ongoing study using data from 5 regional diagnostic centres in a pan-Canadian mutation testing program, the median time for receipt of samples by test centres was 7 days and the time for centres to complete tests and report results was 11 days 12 . That study suggests that EGFR mutation testing is feasible.…”

Section: Egfr Mutation Testingmentioning

confidence: 99%

“…These mutations are found in approximately 10% of patients from North America and in 33% of patients from East Asia, with most being found in female never-smokers with adenocarcinoma histology 11 (Figure 1). An ongoing study collecting data from a pan-Canadian EGFR mutation testing program found that 17.6% of samples (279 of 1588) were positive for exon 19 deletion and exon 21 L858R point mutation 12 . In almost all cases, EGFR mutations are non-overlapping with other oncogenic mutations such as KRAS and ALK.…”

mentioning

confidence: 99%

A Personalized Approach to Treatment: Use of egfr Tyrosine Kinase Inhibitors for the Treatment of Non-Small-Cell Lung Cancer in Canada

et al. 2012

View full text Add to dashboard Cite

Lung cancer is one of the most commonly diagnosed malignancies and the leading cause of cancer-related mortality in Canada. The heterogeneity of nsclc and the importance of linking new targeted agents to the appropriate disease subtype require an individualized approach to treatment. In patients with EGFR (epidermal growth factor receptor gene) mutations, egfr tyrosine kinase inhibitors (tkis) provide a highly effective treatment option, with improved toxicity compared with standard chemotherapy. However, the identification of mutation-positive patients is limited by a lack of funding for testing. The length of time required to receive test results and insufficient tissue from biopsies are additional limitations. In Canada, the use of egfr-tkis varies based on differences in provincial funding for both testing and treatment. With improvements in testing and access to funding for treatment, targeted use of egfr-tkis may greatly improve outcomes in nsclc.

show abstract

Population-based pan-Canadian EGFR-mutation testing program.

Cited by 2 publications

References 0 publications

Challenges in Implementing Personalized Medicine for Lung Cancer within a National Healthcare System

Challenges in Implementing Personalized Medicine for Lung Cancer within a National Healthcare System

A Personalized Approach to Treatment: Use of egfr Tyrosine Kinase Inhibitors for the Treatment of Non-Small-Cell Lung Cancer in Canada

Contact Info

Product

Resources

About